PHIN-214

PHIN-214 is a novel small peptide prodrug developed as a derivative of terlipressin, designed to treat portal hypertension and refractory ascites in patients with liver cirrhosis. It acts as a partial agonist of the vasopressin receptor 1A (V1a), providing milder vasopressor activity compared to full agonists like terlipressin, which allows for safer subcutaneous administration and reduces the risk of ischemia or injection site reactions. After administration, PHIN-214 is rapidly metabolized into its active form, PHIN-156, which activates V1a receptors on arterial smooth muscle. This leads to mesenteric arterial vasoconstriction, reduced splanchnic blood flow and portal pressure, increased systemic arterial pressure (preventing activation of the renin-angiotensin-aldosterone system), improved kidney perfusion, glomerular filtration rate (GFR), and creatinine clearance. The drug’s pharmacokinetic profile supports once-daily dosing suitable for long-term therapy at home rather than requiring intravenous infusion[1][2][4][5][6]. PHIN-214 is currently in clinical development with ongoing Phase 1b/2 trials for decompensated cirrhosis; it offers potential advantages over existing therapies by enabling subcutaneous self-administration outside hospital settings[3][4][5]. Its mechanism targets clinically validated pathways involved in portal hypertension management.